<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TELITHROMYCIN</span><br/>(tel-i-thro-my'sin)<br/><span class="topboxtradename">Ketek, Ketek Pak<br/></span><b>Classifications:</b> <span class="classification">antiinfectives</span>; <span class="classification">antibiotic, macrolide</span>; <span class="classification">ketolide</span><br/><b>Prototype: </b>Erythromycin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Telithromycin concentrates in phagocytes where it works against intracellular respiratory pathogens.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Its broad spectrum of activity is effective against respiratory pathogens, including erythromycin- and penicillin-resistant
         pneumococci.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis (AECB), and mild to moderate community-acquired
         pneumonia due to susceptible bacteria.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Congenital QT prolongation, ongoing proarrhythmic conditions such as hypokalemia, hypomagnesemia, significant bradycardia,
         concurrent administration of Class IA or Class III antiarrhythmic drugs; macrolide antibiotic hypersensitivity; myasthenia
         gravis, unless no other therapeutic option is available; pregnancy (category C); severe renal impairment or renal failure;
         concurrent administration with pimozide; viral infections. Safety and efficacy in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of GI disease; hepatic disease; history of hepatitis or jaundice; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 800 mg once daily for 5 d<br/><br/><span class="indicationtitle">Community-Acquired Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 800 mg once daily for 710 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not administer concurrently with simvastatin, lovastatin, atorvastatin, Class 1A (e.g., quinidine, procainamide) or Class
            III (e.g., dofetilide) antiarrhythmic agents. See drug interactions for other prohibited drug combinations.
         </li>
<li>Store at 15°30° C (59°86° F). Keep container tightly closed. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">CV:</span> Potential to cause QTc prolongation. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea,</span> nausea, vomiting, loose stools, dysgeusia. <span class="typehead">Metabolic:</span> Elevated LFTs. <span class="typehead">Musculoskeletal:</span> May exacerbate myasthenia gravis. <span class="typehead">Special Senses:</span> Blurred vision, diplopia, difficulty focusing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug<b></b>
         			:</span>
<b>Pimozide</b> may cause life-threatening arrhythmias; may increase concentrations of <b>atorvastatin, lovastatin, simvastatin, midazolam</b>
<b>,</b> other <span class="classification">benzodiazepines</span>; <b>rifampin</b> decreases telithromycin levels; <span class="classification">ergot derivatives</span>
<b>(</b>
<b>ergotamine, dihydroergotamine</b>
<b>)</b> may cause severe peripheral vasospasm; <b>theophylline</b> may exacerbate adverse GI effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 57% bioavailable. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Metabolism:</span> 50% metabolized in liver by CYP3A4, 50% metabolized by CYP-independent mechanisms. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG in patients at risk for QTc interval prolongation (i.e., bradycardia).</li>
<li>Withhold drug and notify physician for S&amp;S of QTc interval prolongation such as dizziness or fainting; liver dysfunction.</li>
<li>Lab tests: baseline LFTs, BUN and creatinine, serum potassium.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Stop taking drug and notify physician for episodes of dizziness or fainting; jaundice (yellow color of the skin and/or eyes).</li>
<li>Exercise caution when engaging in potentially hazardous activities; visual disturbances (e.g., blurred vision, difficulty
            focusing, double vision) are potential side effects of this drug. If visual problems occur, avoid quick changes in viewing
            between close and distant objects.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>